Invivyd (NASDAQ:IVVD) Receives "Sell (D-)" Rating from Weiss Ratings

Invivyd (NASDAQ:IVVD - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by investment analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

IVVD has been the topic of several other research reports. D. Boral Capital upped their price target on Invivyd from $1.00 to $2.00 and gave the company a "buy" rating in a research note on Monday. HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Invivyd in a research note on Wednesday, August 27th. Finally, Cantor Fitzgerald began coverage on Invivyd in a research note on Monday. They issued an "overweight" rating and a $10.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $5.14.

Invivyd Stock Up 0.6%

Shares of IVVD opened at $1.64 on Wednesday. Invivyd has a 12-month low of $0.35 and a 12-month high of $2.74. The firm has a market capitalization of $197.03 million, a PE ratio of -1.78 and a beta of 0.57. The stock's fifty day simple moving average is $1.01 and its 200-day simple moving average is $0.81.

Invivyd (NASDAQ:IVVD - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.08). Invivyd had a negative net margin of 238.33% and a negative return on equity of 177.89%. The firm had revenue of $11.79 million for the quarter, compared to analyst estimates of $23.16 million. Analysts anticipate that Invivyd will post -1.64 EPS for the current year.

Insider Activity at Invivyd

In other news, insider Jill Andersen sold 49,402 shares of the firm's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $0.57, for a total transaction of $28,159.14. Following the sale, the insider owned 84,446 shares of the company's stock, valued at $48,134.22. This trade represents a 36.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 277,654 shares of company stock worth $167,215 over the last quarter. Company insiders own 25.40% of the company's stock.

Institutional Investors Weigh In On Invivyd

A number of hedge funds have recently modified their holdings of the business. Invesco Ltd. raised its position in shares of Invivyd by 25.5% during the second quarter. Invesco Ltd. now owns 136,755 shares of the company's stock worth $98,000 after purchasing an additional 27,756 shares during the period. Vanguard Personalized Indexing Management LLC raised its position in shares of Invivyd by 238.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock worth $29,000 after purchasing an additional 28,146 shares during the period. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Invivyd during the second quarter worth about $27,000. 683 Capital Management LLC raised its position in shares of Invivyd by 2.3% during the second quarter. 683 Capital Management LLC now owns 3,070,000 shares of the company's stock worth $2,195,000 after purchasing an additional 70,000 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Invivyd during the first quarter worth about $65,000. Institutional investors and hedge funds own 70.36% of the company's stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.